These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8157450)

  • 21. Stabilization of the attenuated poliovirus type 3 vaccine strain by sucrose.
    Srivastava AK
    Acta Virol; 1989 Mar; 33(2):188-90. PubMed ID: 2569817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.
    Sanders BP; de Los Rios Oakes I; van Hoek V; Bockstal V; Kamphuis T; Uil TG; Song Y; Cooper G; Crawt LE; Martín J; Zahn R; Lewis J; Wimmer E; Custers JH; Schuitemaker H; Cello J; Edo-Matas D
    PLoS Pathog; 2016 Mar; 12(3):e1005483. PubMed ID: 27032093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of live, oral poliovirus vaccine monopools for human immunodeficiency virus type 1 and simian immunodeficiency virus.
    Khan AS; Shahabuddin M; Bryan T; Joshi BH; Lee S; Hewlett IK
    J Infect Dis; 1996 Dec; 174(6):1185-90. PubMed ID: 8940207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains.
    Abdelnabi R; Delang L; Neyts J
    Vaccine; 2017 Mar; 35(10):1370-1372. PubMed ID: 28189401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic basis of attenuation of the Sabin oral poliovirus vaccines.
    Minor PD; Macadam AJ; Stone DM; Almond JW
    Biologicals; 1993 Dec; 21(4):357-63. PubMed ID: 8024751
    [No Abstract]   [Full Text] [Related]  

  • 26. Laboratory tests for live attenuated poliovirus vaccine.
    Arya SC
    Biologicals; 1998 Sep; 26(3):245-6. PubMed ID: 10208726
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of hydrostatic pressure on the stability and thermostability of poliovirus: a new method for vaccine preservation.
    Ferreira E; Mendes YS; Silva JL; Galler R; Oliveira AC; Freire MS; Gaspar LP
    Vaccine; 2009 Aug; 27(39):5332-7. PubMed ID: 19616496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine-related issues.
    Rev Infect Dis; 1982; 4(5):972-7. PubMed ID: 7146734
    [No Abstract]   [Full Text] [Related]  

  • 29. Live attenuated oral poliovirus vaccine.
    Melnick JL
    Rev Infect Dis; 1984; 6 Suppl 2():S323-7. PubMed ID: 6330836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.
    Foiadelli T; Savasta S; Battistone A; Kota M; Passera C; Fiore S; Bino S; Amato C; Lozza A; Marseglia GL; Fiore L
    BMC Infect Dis; 2016 Jun; 16():277. PubMed ID: 27287521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in vaccine stability monitoring technology.
    Zweig SE
    Vaccine; 2006 Aug; 24(33-34):5977-85. PubMed ID: 16759766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on the failure time of the vaccine vial monitor used for oral poliovirus vaccine at 25 ℃ and 37 ℃].
    Wen CK; Zhou CN; Jiang L; Chen ZG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Mar; 51(3):248-251. PubMed ID: 28260340
    [No Abstract]   [Full Text] [Related]  

  • 33. Determination of antigenic properties of vaccine derived poliovirus strains.
    Pliaka V; Achilleos C; Kyriakopoulou Z; Tsakogiannis D; Ruether IG; Gartzonica C; Levidiotou-Stefanou S; Markoulatos P
    Vaccine; 2010 Dec; 29(1):26-33. PubMed ID: 20974307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. POLIOVIRUS ANTIBODY TWO YEARS AFTER ORAL TRIVALENT VACCINE (SABIN STRAINS).
    CABASSO VJ; NOZELL H; RUEGSEGGER JM; COX HR
    JAMA; 1964 Oct; 190():248-50. PubMed ID: 14246605
    [No Abstract]   [Full Text] [Related]  

  • 35. [Genetic recombination in vaccine poliovirus: comparative study in strains excreted in course of vaccination by oral poliovirus vaccine and circulating strains].
    Haddad-Boubaker S; Ould-Mohamed-Abdallah MV; Ben-Yahia A; Triki H
    Pathol Biol (Paris); 2010 Dec; 58(6):420-5. PubMed ID: 19299091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CURRENT STATUS OF MEASLES AND ORAL POLIOVIRUS VACCINES.
    MACLEOD DR
    Can Med Assoc J; 1964 Nov; 91(21):1118-22. PubMed ID: 14229761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3.
    Minor PD; Dunn G; Evans DM; Magrath DI; John A; Howlett J; Phillips A; Westrop G; Wareham K; Almond JW
    J Gen Virol; 1989 May; 70 ( Pt 5)():1117-23. PubMed ID: 2543771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are childhood immunization programmes in Australia at risk? Investigation of the cold chain in the Northern Territory.
    Miller NC; Harris MF
    Bull World Health Organ; 1994; 72(3):401-8. PubMed ID: 8062398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The molecular biology of poliovaccines.
    Minor PD
    J Gen Virol; 1992 Dec; 73 ( Pt 12)():3065-77. PubMed ID: 1335021
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries.
    Karp CL; Lans D; Esparza J; Edson EB; Owen KE; Wilson CB; Heaton PM; Levine OS; Rao R
    Vaccine; 2015 Jul; 33(30):3471-9. PubMed ID: 26055297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.